1. Home
  2. AEI vs INKT Comparison

AEI vs INKT Comparison

Compare AEI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alset Inc. (TX)

AEI

Alset Inc. (TX)

N/A

Current Price

$1.79

Market Cap

54.1M

Sector

Real Estate

ML Signal

N/A

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

N/A

Current Price

$12.00

Market Cap

52.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AEI
INKT
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.1M
52.5M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
AEI
INKT
Price
$1.79
$12.00
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$35.00
AVG Volume (30 Days)
17.9K
6.8K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$16,238,200.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$8.48
52 Week High
$4.55
$16.80

Technical Indicators

Market Signals
Indicator
AEI
INKT
Relative Strength Index (RSI) 74.13 57.62
Support Level $1.47 $10.72
Resistance Level $1.90 $11.74
Average True Range (ATR) 0.11 0.52
MACD 0.07 0.10
Stochastic Oscillator 89.60 82.80

Price Performance

Historical Comparison
AEI
INKT

About AEI Alset Inc. (TX)

Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: Real Estate, Digital Transformation Technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Share on Social Networks: